Bachem
  • Products & Services
    • CMC Development
      • Peptide NCES
      • Oligonucleotide NCEs
    • Commercial APIs
      • Commercial NCEs
      • Commercial Generics
    • Research & Specialties
      • Catalog Peptides
      • Custom Peptide Synthesis
      • Amino Acid Derivatives
      • Diagnostics
      • Cosmetic Peptides
    • Services & Capabilities
      • Project Management
      • Quality & Regulatory
      • Analytical capabilities
      • GMP Production
      • Research Grade Production
      • Supply & vertical integration
  • About Bachem
    • Company overview
      • Our Purpose
      • Our vision & strategy
      • Our Leadership
      • Our History
      • Our Locations
    • Innovation
      • Innovation matters
      • Innovation collaborations
    • Sustainability
      • People & culture
      • Safeguarding the environment
      • Acting ethically
    • Investors & Media
      • Reports & Presentations
      • Financial events
      • Media Library
      • Press archive
  • News & Events
    • News
    • Events
  • Careers
  • Contact
Select Page

US FDA audit

October 18, 2010

Bachem is proud to announce the successful completion of a full GMP inspection by the US FDA of its Bubendorf (Switzerland) manufacturing site.

The inspection was conducted by 2 investigators on four inspection days during September 24th – 29th and resulted very successfully with no form FDA 483 or other observations, confirming the high level of GMP compliance of Bachem’s Bubendorf site.

← Professor Dr. Helma Wennemers of the University of Basel receives the Leonidas Zervas Award sponsored by Bachem Bachem regains the upswing - significantly improved Business Performance in second semester →

Meet Bachem: Johannes Kremser, Group Leader R&D

GalNAc conjugates: Delivery service to the liver!

Bachem announces the launch of their new website

Change in the Board of Directors of Bachem Holding AG

Bachem reports excellent results in 2020 – Sales exceed 400 million CHF for the first time

Peptide Trends February 2021

A New Turn in Peptide Purification

Innovation management

Peptide Trends January 2021

Bachem receives the Top Innovator Award from Alpora

Bachem Expanding into Oligonucleotides

Peptide Trends November 2020

Microspheres and Nanoparticles for Peptide Delivery

Changes to the Bachem Corporate Executive Committee

Peptide Trends October 2020

Peptide Trends September 2020

Oligonucleotide Trends September 2020

First half of 2020: Record sales and faster growth

Peptide Trends July 2020

Peptide Trends June 2020

Knowledge Center
General Conditions
Legal Statement
Privacy Policy
Imprint
Contact
  •  

  •  

  •  

  •  

  •